A new mRNA company with non-immunogenic, non-toxic mRNA platform...3 Key Platform Technology; mRNA-based gene editing therapies and cell reprogramming therapies "plans to enter clinical next year"
A new mRNA company has emerged in the global biotechnology industry. Novellus, located in Boston, plans to enter clinical trials next year with a first-in-class mRNA gene editing therapy for a rare devasting genetic disease. Novellus is also considering an IPO in 2019. To date, companies in clinical trials with mRNA products have mainly focused on the development of vaccines, whereas Novellus believes that it holds the unique position of being able to address both genetic diseases and regenerative medicine using mRNA.
Executive Vice President Paul Sowyrda introduced reporters from the Biospectator to the company’s therapeutic development strategy. In their new lab in Boston, the reporter met Dr. Frank Borriello M.D., a strategic consultant to the company, and Dr. Matthew Angel, the CSO, as well as Mr. Sowyrda.